Skip to main content

Prostate cancer

Austria, Europe
2017
EANM, European Association of Nuclear Medicine
f8a5e5152a56b7390e83035856d02f41.jpg

European Association of Nuclear Medicine: Prostate cancer patients who are resistant to hormone treatment used to have a poor prognosis. Until recently, the diagnostic and therapeutic possibilities had been limited, but now innovative developments in nuclear medicine imaging and therapy open up promising pathways. Novel substances used with PET/CT (positron-emission tomography combined with computed tomography) not only allow for better diagnosis but also offer treatment options where other therapies have failed.